These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 19096009)

  • 21. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
    Liu JH; Liu CC; Yen CC; Gau JP; Wang WS; Tzeng CH
    Int J Cancer; 2009 Jul; 125(1):71-7. PubMed ID: 19291793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma.
    Ory B; Ramsey MR; Wilson C; Vadysirisack DD; Forster N; Rocco JW; Rothenberg SM; Ellisen LW
    J Clin Invest; 2011 Feb; 121(2):809-20. PubMed ID: 21293058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MDM2 mediates p73 ubiquitination: a new molecular mechanism for suppression of p73 function.
    Wu H; Leng RP
    Oncotarget; 2015 Aug; 6(25):21479-92. PubMed ID: 26025930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
    Lau LM; Nugent JK; Zhao X; Irwin MS
    Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p53 Activity Dominates That of p73 upon Mdm4 Loss in Development and Tumorigenesis.
    Tashakori M; Zhang Y; Xiong S; You MJ; Lozano G
    Mol Cancer Res; 2016 Jan; 14(1):56-65. PubMed ID: 26527653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gain of cellular adaptation due to prolonged p53 impairment leads to functional switchover from p53 to p73 during DNA damage in acute myeloid leukemia cells.
    Chakraborty J; Banerjee S; Ray P; Hossain DMS; Bhattacharyya S; Adhikary A; Chattopadhyay S; Das T; Sa G
    J Biol Chem; 2010 Oct; 285(43):33104-33112. PubMed ID: 20675383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylation.
    Koida N; Ozaki T; Yamamoto H; Ono S; Koda T; Ando K; Okoshi R; Kamijo T; Omura K; Nakagawara A
    J Biol Chem; 2008 Mar; 283(13):8555-63. PubMed ID: 18174154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism.
    Steele AJ; Prentice AG; Hoffbrand AV; Yogashangary BC; Hart SM; Nacheva EP; Howard-Reeves JD; Duke VM; Kottaridis PD; Cwynarski K; Vassilev LT; Wickremasinghe RG
    Blood; 2008 Nov; 112(9):3827-34. PubMed ID: 18682598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pro-apoptotic TP53 homolog TAp63 is repressed via epigenetic silencing and B-cell receptor signalling in chronic lymphocytic leukaemia.
    Humphries LA; Godbersen JC; Danilova OV; Kaur P; Christensen BC; Danilov AV
    Br J Haematol; 2013 Dec; 163(5):590-602. PubMed ID: 24117128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein.
    Matallanas D; Romano D; Yee K; Meissl K; Kucerova L; Piazzolla D; Baccarini M; Vass JK; Kolch W; O'neill E
    Mol Cell; 2007 Sep; 27(6):962-75. PubMed ID: 17889669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. E1A activates transcription of p73 and Noxa to induce apoptosis.
    Flinterman M; Guelen L; Ezzati-Nik S; Killick R; Melino G; Tominaga K; Mymryk JS; Gäken J; Tavassoli M
    J Biol Chem; 2005 Feb; 280(7):5945-59. PubMed ID: 15572378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tyr99 phosphorylation determines the regulatory milieu of tumor suppressor p73.
    Satija YK; Das S
    Oncogene; 2016 Jan; 35(4):513-27. PubMed ID: 25893286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells.
    Santidrián AF; González-Gironès DM; Iglesias-Serret D; Coll-Mulet L; Cosialls AM; de Frias M; Campàs C; González-Barca E; Alonso E; Labi V; Viollet B; Benito A; Pons G; Villunger A; Gil J
    Blood; 2010 Oct; 116(16):3023-32. PubMed ID: 20664053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DeltaNp73 antisense activates PUMA and induces apoptosis in neuroblastoma cells.
    Simões-Wüst AP; Sigrist B; Belyanskaya L; Hopkins Donaldson S; Stahel RA; Zangemeister-Wittke U
    J Neurooncol; 2005 Mar; 72(1):29-34. PubMed ID: 15803372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Securinine induces p73-dependent apoptosis preferentially in p53-deficient colon cancer cells.
    Rana S; Gupta K; Gomez J; Matsuyama S; Chakrabarti A; Agarwal ML; Agarwal A; Agarwal MK; Wald DN
    FASEB J; 2010 Jun; 24(6):2126-34. PubMed ID: 20133503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The potential anticancer agent PK11195 induces apoptosis irrespective of p53 and ATM status in chronic lymphocytic leukemia cells.
    Santidrián AF; Cosialls AM; Coll-Mulet L; Iglesias-Serret D; de Frias M; González-Gironès DM; Campàs C; Domingo A; Pons G; Gil J
    Haematologica; 2007 Dec; 92(12):1631-8. PubMed ID: 18055986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An essential role for p73 in regulating mitotic cell death.
    Toh WH; Nam SY; Sabapathy K
    Cell Death Differ; 2010 May; 17(5):787-800. PubMed ID: 20010785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential control of TAp73 and DeltaNp73 protein stability by the ring finger ubiquitin ligase PIR2.
    Sayan BS; Yang AL; Conforti F; Tucci P; Piro MC; Browne GJ; Agostini M; Bernardini S; Knight RA; Mak TW; Melino G
    Proc Natl Acad Sci U S A; 2010 Jul; 107(29):12877-82. PubMed ID: 20615966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ubiquitination-dependent degradation of p73 by the mitochondrial E3 ubiquitin ligase Hades.
    Min B; Ryu J; Chi SW; Yi GS
    Biochem Biophys Res Commun; 2015 Nov; 467(2):316-21. PubMed ID: 26435500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.
    Lapalombella R; Andritsos L; Liu Q; May SE; Browning R; Pham LV; Blum KA; Blum W; Ramanunni A; Raymond CA; Smith LL; Lehman A; Mo X; Jarjoura D; Chen CS; Ford R; Rader C; Muthusamy N; Johnson AJ; Byrd JC
    Blood; 2010 Apr; 115(13):2619-29. PubMed ID: 19965642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.